Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ECE1 | P42892 | 10/20 | 1.00 |
| ▸ | MME | P08473 | 10/20 | 1.00 |
| ▸ | ACE | P12821 | 10/20 | 1.00 |
| ▸ | MMP13 | P45452 | 6/20 | 1.00 |
| ▸ | MMP14 | P50281 | 8/20 | 0.66 |
| ▸ | MMP2 | P08253 | 7/20 | 0.66 |
| ▸ | MMP9 | P14780 | 7/20 | 0.66 |
| ▸ | MMP8 | P22894 | 7/20 | 0.66 |
| ▸ | MMP7 | P09237 | 2/20 | 0.65 |
| ▸ | MMP11 | P24347 | 2/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4876681 | 0.89 | ECE1 (1.00) | ECE1MMEACEMMP13 | |
| SCHEMBL3862234 | 0.89 | ECE1 (1.00) | ECE1MMEACEMMP13 | |
| SCHEMBL3866175 | 0.89 | ECE1 (1.00) | ECE1MMEACEMMP13 | |
| SCHEMBL3862250 | 0.86 | ECE1 (1.00) | ECE1MMEACEMMP13 | |
| SCHEMBL4898483 | 0.84 | ECE1 (0.86) | ECE1MMEACEMMP13 | |
| SCHEMBL3862623 | 0.84 | ECE1 (0.86) | ECE1MMEACEMMP13 | |
| SCHEMBL13866603 | 0.84 | ECE1 (0.86) | ECE1MMEACEMMP13 | |
| SCHEMBL3888661 | 0.81 | MME (0.72) | ECE1MMEACEMMP13MMP14 | |
| SCHEMBL3888666 | 0.81 | MME (0.72) | ECE1MMEACEMMP13MMP14 | |
| SCHEMBL3888663 | 0.81 | MME (0.72) | ECE1MMEACEMMP13MMP14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7521469-B2 | Phosphinic amino acid compounds | LES LABORATOIRES SERVIER (FR) | 2009-04-21 | — | — | US | claimed |
| US-20080153890-A1 | Phosphinic Amino Acid Compounds | LES LABORATOIRES SERVER (FR) | 2008-06-26 | — | — | US | claimed |
| US-7521469-B2 | Phosphinic amino acid compounds | LES LABORATOIRES SERVIER (FR) | 2009-04-21 | — | — | US | disclosed |
| US-20080153890-A1 | Phosphinic Amino Acid Compounds | LES LABORATOIRES SERVER (FR) | 2008-06-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080153890-A1 | Phosphinic Amino Acid Compounds | NPR1, NPPA, AADAT | ECE1 419/4885MME 1899/4885ACE 139/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.